Abeona Therapeutics (ABEO) EBITDA (2011 - 2026)

Abeona Therapeutics' EBITDA history runs 16 years deep, the most recent figure standing at -$17.2 million for Q1 2026.

• In Q1 2026, EBITDA fell 42.38% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at $66.2 million (up 250.18% YoY), while the FY2025 annual figure was $71.3 million, up 212.02% from the prior year.
• EBITDA was -$17.2 million for Q1 2026 at Abeona Therapeutics, up from -$20.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $108.9 million in Q2 2025 to a low of -$31.7 million in Q1 2024.
• Historically, EBITDA has averaged -$6.3 million across 5 years, with a median of -$11.8 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA slumped 250.5% in 2024, then soared 1359.97% in 2025.
• A 5-year view of EBITDA shows it stood at -$7.2 million in 2022, then sank by 129.78% to -$16.6 million in 2023, then jumped by 44.43% to -$9.2 million in 2024, then sank by 120.98% to -$20.3 million in 2025, then advanced by 15.24% to -$17.2 million in 2026.
• The last three EBITDA figures came in at -$17.2 million (Q1 2026), -$20.3 million (Q4 2025), and -$5.1 million (Q3 2025), per Business Quant data.